CRO

• 

  AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications

  12:05 PM | March 21, 2017

  NEW YORK, March 21, 2017, AXIM, (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has retained the services of Ora®, Inc., a global Contract Research Organization (“CRO”), to perform the company’s upcoming product development (based on AXIM’s IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world’s leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases.

  Read more

• CAPP – Capstone Financial Group, Inc. Initiates Plans to Acquire a National Independent Broker-Dealer & RIA

  3:01 PM | December 9, 2013

  Capstone Financial Group (PublicWire.com Press Release) –IRVINE, Calif., Dec. 9, 2013 /PRNewswire/ — Capstone Financial Group, Inc. (OTCBB: CAPP), a recently formed financial-services related firm, has initiated plans to acquire a National Independent broker-dealer and RIA for the price of $2 million, Chairman and CEO Darin Pastor announced today. The company is based in the New York Metropolitan area and completion of the acquisition is expected in early 2014. Established in 1999, the national independent broker-dealer and RIA is licensed

  Read more